ARA-290 (aka Cibinetide) is a synthetic peptide derived from erythropoietin (EPO) designed to activate the innate repair receptor (IRR) and produce anti-inflammatory, neuroprotective, and tissue-repair effects without EPO’s red bood-cell-stimulating or pro-thrombotic actions.
Benefits
- Relief of neuropathic pain (especially small-fiber neuropathy)
- Strong anti-inflammatory
- Supports nerve repair/regeneration
- Restores immune balance in autoimmune disorders
- Tissue repair actions in injured, stressed, or ischemic tissues
- Provides adjunctive support for metabolic diseases like Type 2 diabetes, helping nerve complications, lipid/glucose improvements
- Does not produce clinically significant changes in electrolytes, liver, kidney, pancreas, erythrocytes, platelets, or leukocytes
- Improves lipid and glucose metabolism in diabetics
Interactions
- Concomitant use of strong immunosuppressants or biologic anti-inflammatory drugs may amplify immune modulation (caution advised)
- Agents that increase angiogenesis or that affect repair/vascular pathways may theoretically have additive or synergistic effects
- Given the repair/angiogenic axis, close monitoring of anticoagulent and antiplatelet medications is recommended
- Concomitant use of antidiabetic agents may require dose monitoring due to a risk of hypoglycemia
Contraindications
- Do not use if you are pregnant or breastfeeding
- Do not use if you determine that you are hypersensitive to this peptide
- Do not use if you have an active malignancy
- Do not use if you have uncontrolled cardiovascular disease or are at high risk of thrombosis
ARA-290 RECONSTITUTION AND DOSING
4, 8, or 12 week cycles followed by 2, 4, or 6 week washout periods
Subcutaneous Administration
Standard Protocol
Mix with 1.5mL (150 units) of BAC water
30, 45, or 60 units (2, 3, or 4mg), 1x/day, daily
Maximum Protocol
Mix with 1mL (100 units) of BAC water
80 units (8mg), 1x/day, daily, for a maximum of 4 weeks